Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busines”
Debt Financings
Akari Therapeutics Plc incurred debt of $2,826,250 maturing 12-month anniversary of the respective Closing Dates.
“the Company completed its first tranche of closings of the Offering and issued Notes with an aggregate purchase price of $2,261,000 and an aggregate principal amount of $2,826,250”
Sandip Patel was appointed as Director at Akari Therapeutics Plc.
“As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.”
James Neal was appointed as Director at Akari Therapeutics Plc.
“As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.”
Hoyoung Huh was appointed as non-executive chairman at Akari Therapeutics Plc.
“Dr. Huh will serve as the non-executive chairman of the Akari Board as of the Effective Time.”
Donald Williams resigned as Director at Akari Therapeutics Plc.
“Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.”
Wa'el Hashad resigned as Director at Akari Therapeutics Plc.
“Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.”
Robert Bazemore was appointed as director at Akari Therapeutics Plc.
“the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024”
Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.
“Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024”
Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.
“As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.”
Earnings Releases
Akari Therapeutics Plc reported the first quarter ended March 31, 2024 results: net income Net loss was approximately $5.6 million.
“Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter ended March 31, 2024 as well as recent company highlights.”
Restructurings & Charges
Akari Therapeutics Plc announced a restructuring with charges of approximately $3.1 million to $3.2 million (approximately 67% of its total workforce).
“expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $3.1 million to $3.2 million, which includes approximately $1.6 million of non-cash expenses related to vesting of equity awards. The Company expects these costs to be payable through the”
Rachelle Jacques resigned as Director at Akari Therapeutics Plc.
“On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.”
Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.
“the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024”
Melissa Bradford-Klug departed as Chief Operating Officer at Akari Therapeutics Plc.
“our Chief Operating Officer, Melissa Bradford-Klug, was terminated without cause, effective May 1, 2024.”
Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.
“Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.”
Listing & Compliance Notices
Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 5, 2024, Akari Therapeutics, Plc (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”) is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity”
Earnings Releases
Akari Therapeutics Plc reported the full year ended December 31, 2023 results: net income Net loss was approximately $10.0 million for the year ended December 31, 2023.
“Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights”
Material Agreements
Akari Therapeutics Plc entered into Purchase Agreement with certain existing investors valued at approximately $1,615,000 (effective 2024-03-11).
“On March 11, 2024, Akari Therapeutics, Plc (the “ Company ”) entered into a definitive agreement (the “ Purchase Agreement ”) with certain existing investors, pursuant to which the Company agreed to sell and issue in a private placement (the “ Private Placement ”) approximately $1,615,000 of unregistered American Depository Shares (“ ADSs ”)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.